Exhibit 10.2
[***] Certain information in this document has been omitted from this exhibit because it is both
(i) not material and (ii) would be competitively harmful if publicly disclosed.
​
TENTH AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT
This Tenth Amendment (this “Tenth Amendment”), effective April 30 2022 (“Tenth Amendment Effective Date”), is by and between F. Hoffmann-La Roche Ltd, with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland and Hoffmann-La Roche Inc., with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424 U.S.A. (together referred to as “Roche”), and Blueprint Medicines Corporation, with a principal place of business at 45 Sidney Street, Cambridge, Massachusetts 02139 U.S.A. (“BPM”). Capitalized terms used and not otherwise defined in this Tenth Amendment shall have the meanings set forth in the Agreement (as defined below).
WHEREAS, BPM and Roche entered into a Collaboration and License Agreement, dated March 14, 2016, as amended by an amendment, effective April 15, 2016, a second amendment, effective April 27, 2016, a third amendment, effective August 4, 2016, a fourth amendment, effective February 25, 2019, a fifth amendment, effective June 28, 2019, a sixth amendment effective November 1, 2019, a seventh amendment effective December 17, 2019,  an eighth amendment effective April 30, 2020, and a ninth amendment effective January 8, 2021 (collectively, the “Agreement”);
WHEREAS, BPM and Roche desire to amend certain terms under the Agreement related to [***] and the FTE Rate (as defined below), as set forth below;
NOW THEREFORE, Roche and BPM hereby agree as follows:
1.Section 1.86 (Option Period) of the Agreement shall be deleted in its entirety and replaced by the following:
“The term ‘Option Period’ shall mean, for each Collaboration Target, the period beginning on the date the MTD for the first Product for such Collaboration Target is designated by the JDC and ending upon the earliest of (i) the date that such Collaboration Target becomes a Leftover Target, (ii) [***] after Roche’s receipt of the Option Data Package for such Collaboration Target, (iii) the date such Collaboration Target becomes a Terminated Target, (iv) the date upon which a Product (including Backup Compounds) for such Collaboration Target is no longer in GLP Tox Studies, in Phase I Studies, or progressing from GLP Tox Studies to Phase I Studies, or (v) [***] after achievement of Lead Series Identified Criteria has been confirmed by the JRC for such Collaboration Target if Initiation of the GLP Tox Study has not been achieved for such Collaboration Target prior to such date; provided, however, that
		(a)
	[***] for purposes of this clause 1.86(v), [***]. In the event that the JRC subsequently [***]; and


		(b)
	[***] for purposes of this clause 1.86(v), [***].


​

- 1 -



2.In the event that (A) Initiation of the GLP Tox Study [***], (B) prior to [***] the JRC determines [***], or (C) prior to [***] the JRC determines [***] shall not be continued for any other reason, then [***] shall automatically be classified as a “Terminated Target” under the Agreement in all countries in the Territory as if terminated in accordance with Section 21.2.4 (the failure to satisfy the deadline under clause (A) or the occurrence of the trigger under clause (B), as applicable, is hereinafter referred to as the [***]). Notwithstanding the written notice period set forth in such Section 21.2.4, the effective date of termination of such Terminated Target will be the [***]. Further, effective as of the [***] this Tenth Amendment will be deemed to constitute a “Continuation Election Notice” in accordance with Section 21.3.1 and Roche will comply with its obligations under 21.3.1 and 21.3.4; provided that no payment will be due or payable to Roche under Section 21.3.1(f) or 21.3.4.4. As of the [***], (a) the rights and licenses granted by BPM to Roche under the Agreement related to [***] will terminate in their entirety in all countries in the Territory, (b) except as set forth herein, the rights and obligations of the Parties under the Agreement will terminate with respect to [***], (c) Roche’s obligations under Section 20.1 will survive with respect to [***], (d) BPM will solely own all Collaboration Compounds and Other Compounds for [***], including their methods of manufacture and use, and all Patent Rights and Know-How relating thereto, and (e) BPM will have the right to (i) research, develop, manufacture, commercialize and otherwise exploit compounds and products related to [***] outside of the Agreement without any financial obligations to Roche, (ii) publish data and other Know-How related to [***] (including without limitation Collaboration Compounds and Other Compounds for such Terminated Target) generated by or on behalf of the Parties under the Agreement prior to the [***] or thereafter without obtaining prior review or approval from Roche and (iii) disclose, in its sole discretion, in a manner consistent with BPM’s then-current disclosure or publication practices or policies, that such data or Know-How was generated under the Agreement and/or the names and affiliations of the individuals involved in the generation of such data or Know-How, if and as applicable.
3.Consistent with JRC discussions [***], notwithstanding anything to the contrary in the Agreement, (a) [***], (b) the [***] listed on Schedule A [***], and (c) [***].
4.Effective [***], with respect to a Party for any period, personnel costs referenced under Sections 1.39 (Development Costs) and 1.96 (Phase I Development Costs) of the Agreement means the applicable FTE Rate (as defined below) multiplied by the applicable number of FTEs (as defined below) of such Party performing activities during such period in accordance with the applicable Phase I Plan (including applicable Phase I Development Costs) and Development Plan (including Development Costs).
“FTE” means the equivalent of a full-time individual’s work time for a twelve (12) month period, where “full-time” is determined by [***] hours per year.  In the event that any individual who works full-time during a given fiscal year works partially on Collaboration Compounds, Products, Licensed Products or Companion Diagnostics for such Collaboration Targets or in furtherance of the Collaboration and partially on other work outside the Collaboration in the fiscal year, then the full-time equivalent to be attributed to such individual’s work hereunder for such fiscal year shall be equal to the percentage of such individual’s total work time in such fiscal year that such individual spent working on Collaboration Compounds, Products, Licensed Products or Companion Diagnostics for such Collaboration Targets or in furtherance of the Collaboration. FTE efforts shall not include the work of alliance management, executive management and general corporate or administrative personnel.
​
​

- 2 -



“FTE Rate” means [***] per one (1) full FTE per full twelve (12) month Calendar Year; provided, that, starting [***], such rate [***].  Notwithstanding the foregoing, for any Calendar Year during the Term that is less than a full year, the above referenced rate shall be proportionately reduced to reflect such portion of such full Calendar Year.
5.This Tenth Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or other electronic signature) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.
6.This Tenth Amendment shall be effective as of the Tenth Amendment Effective Date. On and after the Tenth Amendment Effective Date, each reference in the Agreement to “this Agreement,” “hereunder,” “hereof,” “herein” or words of like import, and each similar reference in the other documents entered into in connection with the Agreement, shall mean and be a reference to the Agreement, as amended by this Tenth Amendment. Except as specifically amended above, the Agreement shall remain in full force and effect in accordance with its terms and is hereby ratified and confirmed.
7.This Tenth Amendment shall be governed by and construed in accordance with the laws of the State of New York, without reference to its conflict of laws principles, and shall not be governed by the United Nations Convention of International Contracts on the Sale of Goods (the Vienna Convention).
[Signature page follows]
​
​

- 3 -



IN WITNESS WHEREOF, the Parties have caused this Tenth Amendment to be executed by their respective duly authorized representatives as of the Tenth Amendment Effective Date.
​
	Blueprint Medicines Corporation
	    
	​

	​
	​
	​

	/s/ Kathryn Haviland
	​
	​

	​
	​
	​

	Name:
	Kathryn Haviland
	​
	​

	​
	​
	​
	​

	Title:
	President & Chief Executive Officer
	​
	​



​
	​


	​


	​


	​


	​



	F. Hoffmann-La Roche Ltd
	    
	​

	​
	​
	​

	/s/ Markus Keller
	​
	/s/ Stefan Arnold

	​
	​
	​

	Name:
	Markus Keller
	​
	Name:
	Stefan Arnold

	​
	​
	​
	​
	​

	Title:
	Global Alliance & Asset Management Director
	​
	Title:
	Head Legal Pharma



​
	​


	​


	​


	​



	Hoffmann-La Roche Inc.
	    
	​

	​
	​
	​

	/s/ John P. Parise
	​
	​

	​
	​
	​

	Name:
	John P. Parise
	​
	​

	​
	​
	​
	​

	Title:
	Authorized Signatory
	​
	​



​
​

​



Schedule A
​
[***]
​
[***]

​